Insights

Rebecca Robbins, Posted with permission from STAT Plus When drug and device makers need a new chief medical officer or vice president, they often start by turning to executive recruiters. One…
The post Q&A: Three big mistakes drug companies make in rec…

Damian Garde, Posted with permission from STAT Has the age of the biotech blockbuster come to a close? Over the past year, a string of would-be best-sellers, expected to generate…
The post As blockbuster drugs fizzle, biotech looks warily to the next b…

File this under ‘unintended consequences.’ A number of health care organizations are complaining that a final guideline the US Food and Drug Administration recently released for naming both biologic medicines…
The post Americans overspend $73bn on bran…

By  Dylan Scott, Posted with permission from STAT Mark Cuban has something to say about prescription drug prices. The billionaire entrepreneur and Dallas Mavericks owner might not seem like an…
The post Mark Cuban Sounds Off on Drug Prices appeared fir…

What’s in a name? An awful lot when it comes to biosimilars. A newly released survey suggests variations in how biosimilars are named may affect the willingness of pharmacists to…
The post Biosimilar names may affect pharmacist dispensing habits appear…

A new study suggests that a group of biosimilar drugs, which are used to treat such afflictions as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, appear as safe and effective…
The post Some biosimilars are just as good as some pricey …

In the world of healthcare, few topics spark as much debate and confusion as prescription drug pricing. Have you ever […]

Have you ever wondered why some medications seem to cost an arm and a leg, while others are surprisingly affordable? […]